Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

AZD6234

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel

AstraZeneca · Phase 1 · Active, not recruiting · Enrollment 100

NCT07013643

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP)n/rn/rn/rn/r
Cohort-2: AZD6234+AZD9550+EE/LEVO+APAPn/rn/rn/rn/r
Cohort-3: AZD9550 + EE/LEVO + APAPn/rn/rn/rn/r
Cohort-4: AZD6234+AZD9550+EE/LEVO+APAPn/rn/rn/rn/r

Not shown

  • Cohort-1: AZD6234 + EE/LEVO + Acetaminophen (APAP): endpoint not reported
  • Cohort-2: AZD6234+AZD9550+EE/LEVO+APAP: endpoint not reported
  • Cohort-3: AZD9550 + EE/LEVO + APAP: endpoint not reported
  • Cohort-4: AZD6234+AZD9550+EE/LEVO+APAP: endpoint not reported